Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials. 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

I AM NOT A HEALTHCARE PROFESSIONAL

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

MET in NSCLC and mCRC (HCPs Only)

What is precision medicine?

  • Precision medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person”1
  •  In oncology, precision medicine is further defined as “the use of therapeutics that are expected to confer benefit to a subset of patients whose cancer displays specific molecular or cellular features (most commonly genomic changes and changes in gene or protein expression patterns)”2
  •  Guidelines now recommend testing for several molecular alterations in patients with non-small cell lung cancer (NSCLC), including EGFR, ALK, ROS1, KRAS, BRAF, NTRK, RET, ERBB2 and MET alterations, which can be used to guide treatment decisions3

What are MET alterations?

  • MET is crucial for normal biological processes, including embryonic and organ development, as well as tissue repair and wound healing4,5
  • Alterations to the MET gene can cause aberrant activation of the MET signaling pathway, which can drive tumor growth through increased cell proliferation, survival, invasion, and metastasis4,5
  • The most common types of MET gene alterations in NSCLC include MET exon 14 skipping and MET amplification4,5 
  • These MET alterations can be identified via tissue or liquid biopsy6-8

MET dysregulation and rationale for targeting in NSCLC

 
Tepotinib is under clinical investigation in several countries. The safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.
 

What is tepotinib?

  • Tepotinib is a kinase inhibitor that targets mesenchymal-epithelial transition (MET) gene alterations⁹
  • Tepotinib inhibits hepatocyte growth factor (HGF)-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways. In vitro, tepotinib inhibited tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells4,5,9
  • Tepotinib is currently being investigated in clinical trials for the treatment of patients with NSCLC and CRC MET amplification6-8,10

INSIGHT 2 clinical trial HCP resources

PERSPECTIVE clinical trial HCP resources

 

 

  1. National Institutes of Health, US National Library of Medicine. What is precision medicine? Accessed May 12, 2020. https://ghr.nlm.nih.gov/primer/precisionmedicine/definition
  2. Yates LR, et al. Ann Oncol. 2018;29(1):30-35.
  3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V3.2020. Accessed May 12, 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
  4. Drilon A, et al. J Thorac Oncol. 2017;12(1):15–26.
  5. Wu YL, et al. Cancer Treat Rev. 2017;61:70-81.
  6. Paik PK, et al. J Clin Oncol. 2019;37(15 suppl). Abstract 9005.
  7. Salgia R, et al. Cancer Treat Rev. 2020;87:102002.
  8. Yang JCH, et al. Ann Oncol. 2019;30(suppl 9):ix157-ix181. Abstract 503P.
  9. Bladt F, et al. Clin Cancer Res. 2013;19(11):2941-2951.
  10. Tabernero J, et al. J Clin Oncol. 2021;39(3 suppl). Abstract TPS149.